UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000054174
Receipt number R000061302
Scientific Title Real-world effectiveness of hypertensive drugs in the treatment of bipolar disorder: A nationwide within-individual study
Date of disclosure of the study information 2024/04/17
Last modified on 2024/04/17 10:51:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effectiveness of hypertensive drugs for the treatment of bipolar disorder

Acronym

HYP-BD

Scientific Title

Real-world effectiveness of hypertensive drugs in the treatment of bipolar disorder: A nationwide within-individual study

Scientific Title:Acronym

HYP-BD

Region

Japan


Condition

Condition

Bipolar disorder

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to compare the hazard of psychiatric admission during the period of specifi c hypertensive drug use to the non-use period of that drupatients diagnosed with bipolar disorder.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Time to psychiatric hospitalization: The follow-up will start at the next day of the index date for outpatients and the next day of the discharge date fotime will be reset when an outcome event occurs and re-start follow-up at the next day of the discharge date. The follow-up will end at death or on May 31/2023.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Defi nitive primary diagnosis of bipolar disorder during outpatient psychiatric visits or psychiatric hospitalization during 1 April 2013 and 31 March date will be considered the index date.
2) At least two prescriptions of lithium, each with a dosage of >=200 mg per day in the study period.
3) Aged 20 years or older at the index date.
4) Enroll in the database at least 365 days prior to the index date.
5) No history of a diagnosis of dementia prior to the index date.

Key exclusion criteria

Not applicable.

Target sample size

50000


Research contact person

Name of lead principal investigator

1st name Tadafumi
Middle name
Last name Kato

Organization

Juntendo University

Division name

Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan

TEL

+81-3-5802-1070

Email

tadafumi.kato@juntendo.ac.jp


Public contact

Name of contact person

1st name Tadafumi
Middle name
Last name Kato

Organization

Juntendo University

Division name

Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan

TEL

+81-3-3813-3111

Homepage URL


Email

tadafumi.kato@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name

Tadafumi Kato


Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan

Tel

+81-3-3813-3111

Email

hongo-rinri@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 04 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 02 Month 27 Day

Date of IRB


Anticipated trial start date

2024 Year 04 Month 17 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Nothing to note


Management information

Registered date

2024 Year 04 Month 17 Day

Last modified on

2024 Year 04 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061302


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name